Ala Obaid
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Ala Obaid has a total of 4 co-authors. Here are the top co-authors by number of shared publications:
Alain Kwizera
Division of Surgical Oncology, Baylor University Medical Center, Dallas, Texas
1 shared publication- Charles Rubarth
Division of Surgical Oncology, Baylor University Medical Center, Dallas, Texas
1 shared publication Daniel Tran
Division of Surgical Oncology, Baylor University Medical Center, Dallas, Texas
1 shared publication- John T. Preskitt
Division of Surgical Oncology, Department of Surgery, Baylor Scott and White Health
1 shared publication
Latest Publications
- Open Access
- 6 December 2022
- Published by Taylor & Francis in Baylor University Medical Center Proceedings
- Vol. 36 (2) , 201-204
Use of indocyanine green for sentinel lymph node biopsy in melanoma
Sentinel lymph node (SLN) biopsy for cutaneous melanoma is a critical part of designing therapy for the skin malignancy. A retrospective review of 54 patients with cutaneous melanoma who underwent SLN biopsy guided by both radiotracer injection and indocyanine green (ICG) fluorescent dye compared the accuracy of identifying the SLN using each method. Patients were injected preoperatively with radiotracer at the site of the primary melanoma and intraoperatively with 2.5 mg of ICG. The detection of the SLN was compared between the two methods. Patients were followed to determine local recurrence and survival from 5 months to 4 years. ICG and radiotracer identified the SLN in 52 of 54 patients. In those patients who mapped, 52 of 52 showed mapping to the same node or nodes. The rate of cancer involvement in the identified node was 19.2% for both techniques. There was no difference in recurrence or survival between the two methods of SLN identification in short follow-up. In conclusion, ICG injection and mapping to identify SLN in cutaneous melanoma is confirmatory for radiotracer mapping and in the future may be an accurate and less costly method for SLN biopsy in cutaneous melanoma.
- 6 December 2022
- Published by Taylor & Francis in Baylor University Medical Center Proceedings
- Vol. 36 (2) , 201-204
Open AccessUse of indocyanine green for sentinel lymph node biopsy in melanoma
Sentinel lymph node (SLN) biopsy for cutaneous melanoma is a critical part of designing therapy for the skin malignancy. A retrospective review of 54 patients with cutaneous melanoma who underwent SLN biopsy guided by both radiotracer injection and indocyanine green (ICG) fluorescent dye compared the accuracy of identifying the SLN using each method. Patients were injected preoperatively with radiotracer at the site of the primary melanoma and intraoperatively with 2.5 mg of ICG. The detection of the SLN was compared between the two methods. Patients were followed to determine local recurrence and survival from 5 months to 4 years. ICG and radiotracer identified the SLN in 52 of 54 patients. In those patients who mapped, 52 of 52 showed mapping to the same node or nodes. The rate of cancer involvement in the identified node was 19.2% for both techniques. There was no difference in recurrence or survival between the two methods of SLN identification in short follow-up. In conclusion, ICG injection and mapping to identify SLN in cutaneous melanoma is confirmatory for radiotracer mapping and in the future may be an accurate and less costly method for SLN biopsy in cutaneous melanoma.